How Clinical Trials are Changing Kidney Cancer Treatment | Science in Action | Belzutifan Explained

Join leading kidney cancer specialists from Moffitt Cancer Center and the University of Florida for an in-depth discussion on the latest advances in kidney cancer treatment and clinical trials. In this Judy Nicholson Kidney Cancer Foundation patient support webinar, Science in Action, experts break down the science behind Belzutifan (Welireg), a promising newer therapy being studied across multiple kidney cancer settings — including advanced metastatic disease and post-surgery treatment. Topics covered in this webinar include: • What Belzutifan (Welireg) is and how it works • Understanding HIF-2alpha and kidney cancer biology • Current FDA-approved uses for Belzutifan • Latest LIGHTSPARK clinical trial updates • Combination therapy with immunotherapy and VEGF inhibitors • Side effects including anemia and low oxygen levels • Adjuvant treatment after kidney cancer surgery • Future directions in kidney cancer research • Questions from kidney cancer patients and caregivers Featured Speakers: • Dr. Jonathan Chatzkel – Moffitt Cancer Center • Dr. Jess DeLaune - University of Florida • Dr. Mitchell Hayes – Moffitt Cancer Center • Dr. Mike Liu – Moffitt Cancer Center This discussion is designed to help patients, caregivers, and advocates better understand emerging treatment options and the rapidly evolving landscape of renal cell carcinoma care. To view chatroom notes from the open forum, visit this link: https://www.dropbox.com/scl/fi/cyl2pa... ------------------------------------------------------------------------- The Judy Nicholson Kidney Cancer Foundation is committed to empowering patients through education, support, and access to expert-led conversations. Learn more about the Judy Nicholson Kidney Cancer Foundation: www.jnfkidneycancer.org Subscribe for more kidney cancer education, patient support webinars, nutrition guidance, survivor stories, and medical updates. #KidneyCancer #RenalCellCarcinoma #Belzutifan #Welireg #CancerResearch #ClinicalTrials #KidneyCancerAwareness #Immunotherapy #MoffittCancerCenter #JNF